Main Article Content

Dr. Arvinder Singh




Vasculitides are a heterogeneous group of chronic progressive remitting and relapsing inflammatory diseases of blood vessels with serious morbidity and mortality due to disease itself and its treatment with corticosteroids and other immunosuppressive drugs. At present, disease-specific biomarkers are not available to assess vasculitis activity and damage, so various clinical tools for the assessing disease activity, disease and treatment-induced organ damage, and prognosis are required for clinical practice and research purposes. These clinical and research tools have dramatically supported good structured clinical research and validated outcome measures as well as clinical record keeping and management of these disorders. In this article, we intend to analyze some of these clinical tools in relation to disease activity and prognosis in a clinical setting.

Abstract 59 | pdf Downloads 28


1. A Adebajo, L Dunkley (2018), The ABC of rheumatology, the fifth edition, published by Wiley Blackwell, Chapter 23, vasculitis and related rashes, page 155.
2. Alexandra, V., Alfred, M., Bernhard, H., et al. (2004), Current status of outcome measures in vasculitis: Focus on Wegener’s granulomatosis and microscopic polyangiitis. Report from OMERACT 7. [online]. Available at: [accessed on 20 MAY 2021].
3. Biscetti, F., Carbonella, A., Parisi, F., Bosello, S. L., Schiavon, F., Padoan, R., Gremese, E., & Ferraccioli, G. (2016). The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU). Medicine, 95(48), e5506.
4. C., Walsh, M., Westman, K., & European Vasculitis Study Group (2011). Long-term patient survival in ANCA-associated vasculitis. Annals of the rheumatic diseases, 70(3), 488–494.
5. De Groot, K., Gross, W.L., Herlyn, K. and Reinhold-Keller, E. (2001) ‘Development and validation of a disease extent index for Wegener's granulomatosis’ Clinical nephrology, 55(1), pp.31-38.
6. Dolezalova, P., Price-Kuehne, F., Özen, S., Benseler, S., Cabral, D., Anton, J., Brunner, J., Cimaz, R., O'Neil, K., Wallace, C., Wilkinson, N., Eleftheriou, D., Demirkaya, E., Böhm, M., Krol, P., Luqmani, R. and Brogan, P. (2012) ‘Disease activity assessment in childhood vasculitis: development and preliminary validation of the Paediatric Vasculitis Activity Score
(PVAS)’, Annals of the Rheumatic Diseases, 72(10), pp.1628-1633.
7. Exley, A.R., Bacon, P.A., Luqmani, R.A., Kitas, G.D., Carruthers, D.M. and Moots, R. (1998). Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). British Journal of Rheumatology, [online] 37(1), pp.57–63. Available at: [Accessed 15 May 2021].
8. EUVAS (2020). Disease scoring by European Vasculitis Society. Available at: (Accessed 15 May 2021)
9. Floris, A., Goodfellow, N., Sznajd, J., Wawrzycka-Adamczyk, K., Querin, H., Craven, A., Rosa, J., Merkel, P.A., Watts, R.A., Luqmani, R.A. and Investigators, on behalf of D. (2016). OP0055 Using The Birmingham Vasculitis Activity Score as A Screening Tool in Patients with Suspected Vasculitis. Annals of the Rheumatic Diseases, [online] 75(Suppl 2), pp.75–75. Available at: [Accessed 28 May 2021].
10. Flossmann, O., Bacon, P., de Groot, K., Jayne, D., Rasmussen, N., Seo, P., Westman, K. and Luqmani, R. (2007). Development of comprehensive disease assessment in systemic vasculitis.
Annals of the Rheumatic Diseases, [online] 66(3), pp.283–292. Available at: [Accessed 15 May 2021]
11. Flossmann, O., Berden, A., de Groot, K., Hagen, C., Harper, L., Heijl, C., Höglund, P., Jayne,
D., Luqmani, R., Mahr, A., Mukhtyar, C., Pusey, C., Rasmussen, N., Stegeman, Ponte, C., Sznajd, J., O'Neill, L., & Luqmani, R. A. (2014). Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases. Clinical and experimental rheumatology, 32(5 Suppl 85),.
12. Haris, Á., Polner, K., Arányi, J., Braunitzer, H., Kaszás, I., Rosivall, L., Kökény, G. and Mucsi, I. (2017) ‘Simple, readily available clinical indices predict early and late mortality among patients with ANCA-associated vasculitis’ BMC Nephrology, 18(1), pp. 76. Available at: DOI:
13. Luqmani, R. (2015) ‘Disease assessment in systemic vasculitis’, Nephrology Dialysis Transplantation, 30, pp. i76-i82. Available at: doi: 10.1093/ndt/gfv002.
14. Mukhtyar, C., Lee, R., Brown, D., Carruthers, D., Dasgupta, B., Dubey, S., Flossmann, O., Hall,
C., Hollywood, J., Jayne, D., Jones, R., Lanyon, P., Muir, A., Scott, D., Young, L. and Luqmani, R.A. (2009). Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Annals of the Rheumatic Diseases, [online] 68(12), pp.1827–1832. Available at:
20multisystem%20clinical%20assessment [Accessed 28 May 2021]
15. Ntatsaki, E., Carruthers, D., Chakravarty, K., D'Cruz, D., Harper, L., Jayne, D., Luqmani, R., Mills, J., Mooney, J., Venning, M., Watts, R. A., & BSR and BHPR Standards, Guidelines and Audit Working Group (2014). BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis. Rheumatology (Oxford, England), 53(12), 2306–2309.
16. (2014) Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis | Guidance | NICE. [online] Available at: antibody associated-rituximab-with-glucocorticoids-appraisal-consultation-document> [Accessed 14 May 2021].
17. Özdemir, U., Ortaç Ersoy, E., Yüksel, R. C., Kaya, E., Aygencel, G., Türkoğlu, M., Topeli, A., Güven, M., Sungur, M., & Altintaş, N. D. (2020). Value of prognostic scores in antineutrophil cytoplasmic antibody (ANCA) associated vasculitis patients in intensive care unit: a multicenter retrospective cohort study from Turkey. Turkish journal of medical sciences, 50(5), 1223–1230.
18. Peter, A et al. (2005) ‘Current Status of Outcome Measures in Vasculitis Focus on Wegener’s Granulomatosis and Microscopic Polyangiitis. Report from OMERACT 7’, The Journal of Rheumatology, 32(12), pp. 2488-2495.
19. Ponte, C., Sznajd, J., Neil, l., Luqmani, R. (2014) ‘Optimization of vasculitis disease assessments in clinical trials, clinical care and long-term databases’ Clinical and Experimental Rheumatology, 32 Suppl 85(5), pp. 118-125.
20. Robson, J., Dawson, J., Doll, H., Cronholm, P., Milman, N., Kellom, K., Ashdown, S., Easley,
E., Gebhart, D., Lanier, G., Mills, J., Peck, J., Luqmani, R., Shea, J., Tomasson, G. and Merkel,
P., (2018) ‘Validation of the ANCA-associated vasculitis patient-reported outcomes (AAVPRO) questionnaire’ Annals of the Rheumatic Diseases, pp. 1158-1165. Available at:
21. R Watts, S Lane D Scott (2005), PubMed, what is known about the epidemiology of vasculitides, available at:
%20a,an%20incidence%20of%2053%2F100%2C000, accessed on the 12/05/2021
22. Seo, P., Jayne, D., Luqmani, R. and Merkel, P. (2009) ‘Assessment of damage in vasculitis: expert ratings of damage’ Rheumatology, 48(7), pp.823-827.
23. Seo, P., Luqmani, R., Flossman, O., Hellmich, B., Herlyn, K., Hoffman, G., Jayne, D., Kallenberg, C., Langford, C., Mahr, A., Matteson, E., Muhktyar, C., Neogi, T., Rutgers, A.,
Specks, U., Stone, J., Ytterberg, S., Merkel, P. (2007) ‘The Future of Damage Assessment in Vasculitis’ J Rheumatol, 34, pp. 1357- 1371.
24. S Monti, P Delvino, X Puechal et al (2020), EULAR School of rheumatology, ANCA-associated vasculitides and polyarthritis nodosa, available at:, accessed on the 12/05/2021
25. Suppiah, R., Mukhtyar, C., Flossmann, O., Alberici, F., Baslund, B., Batra, R., Brown, D., Holle, J., Hruskova, Z., Jayne, D.R.W., Judge, A., Little, M.A., Palmisano, A., Stegeman, C.,
Tesar, V., Vaglio, A., Westman, K. and Luqmani, R. (2011). A cross-sectional study of the
Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology (Oxford, England), [online] 50(5), pp.899–905. Available
at: [Accessed 28 May 2021].
26. Wilson, A., Bacon, P., Young, S. and Carruthers, D. (2010) ‘Vasculitis Integrated Clinical Assessment Database’ JCR: Journal of Clinical Rheumatology, 16(1), pp.10-14. Available at DOI: 10.1097/RHU.0b013e3181c6813f.